1887
  1. Home
  2. Eurosurveillance
  3. Volume 29, Issue 30, 25/Jul/2024
  4. Article
Editorial Open Access
Like 0
Download

SDG 3: hepatitis

Preview this article:
Preview Magnify

There is no abstract available.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.30.2400462
2024-07-25
2024-12-23
/content/10.2807/1560-7917.ES.2024.29.30.2400462
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/30/eurosurv-29-30-1.html?itemId=/content/10.2807/1560-7917.ES.2024.29.30.2400462&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). Global health sector strategies on viral hepatitis, 2016-2021. Towards ending viral hepatitis. Geneva: WHO; 2016. Available from: https://www.who.int/publications/i/item/WHO-HIV-2016.06
  2. Popping S, Bade D, Boucher C, van der Valk M, El-Sayed M, Sigurour O, et al. The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. J Virus Erad. 2019;5(1):60-6.  https://doi.org/10.1016/S2055-6640(20)30281-8  PMID: 30800429 
  3. World Health Organization (WHO). Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: WHO; 2024. Available from: https://www.who.int/publications/i/item/9789240091672
  4. Dash S, Aydin Y, Widmer KE, Nayak L. Hepatocellular carcinoma mechanisms associated with chronic HCV infection and the impact of direct-acting antiviral treatment. J Hepatocell Carcinoma. 2020;7:45-76.  https://doi.org/10.2147/JHC.S221187  PMID: 32346535 
  5. Vargas-Accarino E, Higuera M, Buti M, Mínguez B. Hepatitis-C-related hepatocellular carcinoma, still a relevant etiology beyond a hepatitis C infection cure. Cancers (Basel). 2024;16(8):1521.  https://doi.org/10.3390/cancers16081521  PMID: 38672603 
  6. European Union (EU) Commission. Europe's beating cancer plan. Brussels: EU Commission; 2023. Available from:https://ec.europa.eu/commission/presscorner/detail/en/ip_23_421
  7. Olafsson S, Tyrfingsson T, Runarsdottir V, Bergmann OM, Hansdottir I, Björnsson ES, et al. Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents. J Intern Med. 2018;283(5):500-7.  https://doi.org/10.1111/joim.12740  PMID: 29512219 
  8. Hleyhel M, Geller J, Sadou A, Naaber P, Kuznetsova T, Vorobjov S, et al. Prevalence of chronic hepatitis C infection in the general population in Estonia: results from a national survey, July to December 2022. Euro Surveill. 2024;29(30):2300651.
  9. Hleyhel M, Popovici O, Leuștean M, Reed S, Sadou A, Furegato M, et al. Prevalence of chronic hepatitis C infection in the general population of Romania: results from a national survey. Euro Surveill. 2024;29(30):2300663.
  10. Coalition for Global Hepatitis Elimination. The National Framework Plan for the viral hepatitis control in Romania, 2019-2030, coordinated by the Ministry of Health Romania (National Program). [Accessed: 28 Aug 2023]. Available from: https://www.globalhep.org/about/partner-programs/national-framework-plan-viral-hepatitis-control-romania-2019-2030
  11. Thomadakis C, Gountas I, Duffell E, Gountas K, Bluemel B, Seyler T, et al. Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis. Lancet Reg Health Eur. 2023;36:100792.  https://doi.org/10.1016/j.lanepe.2023.100792  PMID: 38188273 
  12. European Centre for Disease Prevention and Control (ECDC). Monitoring of the responses to the hepatitis B and C epidemics in EU/EEA countries, 2023. Stockholm: ECDC; 2024. Available from: https://www.ecdc.europa.eu/en/publications-data/monitoring-responses-hepatitis-b-and-c-epidemics-eueea-countries-2023
  13. Marshall AD, Willing AR, Kairouz A, Cunningham EB, Wheeler A, O’Brien N, et al. , Global HCV and HIV Treatment Restrictions Group. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions. Lancet Gastroenterol Hepatol. 2024;9(4):366-82.  https://doi.org/10.1016/S2468-1253(23)00335-7  PMID: 38367631 
  14. Hassanin A, Kamel S, Waked I, Fort M. Egypt’s ambitious strategy to eliminate hepatitis C virus: A case study. Glob Health Sci Pract. 2021;9(1):187-200.  https://doi.org/10.9745/GHSP-D-20-00234  PMID: 33795369 
  15. Surey J, Menezes D, Francis M, Gibbons J, Sultan B, Miah A, et al. From peer-based to peer-led: redefining the role of peers across the hepatitis C care pathway: HepCare Europe. J Antimicrob Chemother. 2019;74(Suppl 5):v17-23.  https://doi.org/10.1093/jac/dkz452  PMID: 31782500 
  16. Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175-81.  https://doi.org/10.2105/AJPH.2017.304132  PMID: 29267061 
  17. Palmateer NE, McAuley A, Dillon JF, McDonald S, Yeung A, Smith S, et al. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data. Addiction. 2021;116(10):2893-907.  https://doi.org/10.1111/add.15459  PMID: 33651446 
  18. Ryan P, Valencia J, Cuevas G, Amigot-Sanchez R, Martínez I, Lazarus JV, et al. Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study. Euro Surveill. 2024;29(29):2300712.  https://doi.org/10.2807/1560-7917.ES.2024.29.29.2300712  PMID: 39027941 
  19. Sheehan Y, Cunningham EB, Cochrane A, Byrne M, Brown T, McGrath C, et al. A ‘one-stop-shop’ point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study. J Hepatol. 2023;79(3):635-44.  https://doi.org/10.1016/j.jhep.2023.04.019  PMID: 37116714 
  20. Maticic M, Pirnat Z, Leicht A, Zimmermann R, Windelinck T, Jauffret-Roustide M, et al. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries. Harm Reduct J. 2020;17(1):89.  https://doi.org/10.1186/s12954-020-00439-3  PMID: 33213481 
  21. Abbott M, MacLachlan JH, Romero N, Matthews N, Higgins N, Lee A, et al. A pilot project harnessing surveillance systems to support clinicians providing clinical care for people diagnosed with hepatitis C in Victoria, Australia, September 2021 to 31 March 2022. Euro Surveill. 2024;29(29):2400028.  https://doi.org/10.2807/1560-7917.ES.2024.29.29.2400028  PMID: 39027939 
  22. Isfordink CJ, van Dijk M, Brakenhoff SM, Kracht PAM, Arends JE, de Knegt RJ, et al. Hepatitis C Elimination in the Netherlands (CELINE): How nationwide retrieval of lost to follow-up hepatitis C patients contributes to micro-elimination. Eur J Intern Med. 2022;101:93-7.  https://doi.org/10.1016/j.ejim.2022.04.024  PMID: 35527178 
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error